Johnson & Johnson
Jan 25, 2011

Johnson & Johnson Reports 2010 Fourth-Quarter and Full-Year Results

2010 Fourth-Quarter Sales of $15.6 Billion Decreased 5.5%; EPS was $0.70
2010 Full-Year Sales of $61.6 Billion Decreased 0.5%; Full-Year EPS was $4.78
Excluding Special Items, 2010 Fourth-Quarter EPS was $1.03, an Increase of 1.0%*
And 2010 Full-Year EPS was $4.76, an Increase of 2.8%*

NEW BRUNSWICK, N.J., Jan. 25, 2011 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.6 billion for the fourth quarter of 2010, a decrease of 5.5% as compared to the fourth quarter of 2009. Operational sales declined 5.1% and the negative impact of currency was 0.4%. Domestic sales declined 8.1%, while international sales declined 3.1%, reflecting an operational decline of 2.3% and a negative currency impact of 0.8%. Worldwide sales for the full-year 2010 were $61.6 billion, a decrease of 0.5% versus 2009. Operational sales declined 1.3% and the positive impact of currency was 0.8%.  Domestic sales declined 4.7%, while international sales increased 3.6%, reflecting operational growth of 1.9% and a positive currency impact of 1.7%.

Net earnings and diluted earnings per share for the fourth quarter of 2010 were $1.9 billion and $0.70 respectively. Fourth-quarter 2010 net earnings included after-tax charges of $922 million representing the net impact of litigation settlements, product liability expense and costs associated with the DePuy ASR® Hip recall. Fourth-quarter 2009 net earnings included an after-tax restructuring charge of $852 million and an after-tax gain of $212 million representing the net impact of litigation settlements. Excluding these special items, net earnings for the current quarter were $2.9 billion and diluted earnings per share were $1.03, representing increases of 0.6% and 1.0%, respectively, as compared to the same period in 2009.*

Net earnings and diluted earnings per share for the full-year 2010 were $13.3 billion and $4.78, respectively. Full-year 2010 net earnings included an after-tax gain of $55 million representing the net impact of litigation settlements, product liability expense and costs associated with the DePuy ASR® Hip recall. Full-year 2009 net earnings included an after-tax restructuring charge of $852 million and an after-tax gain of $212 million representing the net impact of litigation settlements. Excluding these special items, net earnings for the full-year 2010 were $13.3 billion and diluted earnings per share were $4.76, representing increases of 2.9% and 2.8%, respectively, as compared with the full year in 2009.*

The Company announced earnings guidance for full-year 2011 of $4.80 to $4.90 per share, which excludes the impact of special items.

"Although 2010 was a challenging year, the business continued to deliver earnings growth, while investing in the future and emerging a stronger organization," said William C. Weldon, Chairman and Chief Executive Officer. "While we will continue to see near-term pressures on the business for 2011, we remain committed to investing in innovative products, a robust pipeline and talented people who will sustain our growth and increase our market leadership in one of the most important and rewarding industries in the world."

Worldwide Consumer sales of $14.6 billion for the full-year 2010 represented a decrease of 7.7% over the prior year consisting of an operational decline of 8.9% and a positive impact from currency of 1.2%. Domestic sales decreased 19.3%; international sales increased 1.2%, which reflected an operational decline of 1.0% and a positive currency impact of 2.2%.

Sales were significantly impacted by the previously announced recalls of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare Fort Washington, Pa., facility as well as the currency devaluation in Venezuela.  With respect to the McNeil Consumer Healthcare product recalls, Mr. Weldon stated, "We have made a commitment to restoring these products to the levels of quality and compliance that consumers expect of Johnson & Johnson."

Positive contributors to the operational sales results included anti-smoking aids and AVEENO®, Dabao, and JOHNSON'S® skin care products.

Worldwide Pharmaceutical sales of $22.4 billion for the full-year 2010 represented a decrease of 0.6% versus the prior year with an operational decline of 1.0% and a positive impact from currency of 0.4%. Domestic sales decreased 4.0%; international sales increased 4.2%, which reflected an operational increase of 3.4% and a positive currency impact of 0.8%.

Sales results include the strong performance of newly launched products including STELARA™ (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI™ (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA® SUSTENNA™ (paliperidone palmitate) a once-monthly, long-acting, injectable atypical antipsychotic for the acute and maintenance treatment of schizophrenia in adults.

Several other products also had strong operational sales growth including REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA® (darunavir), a treatment for HIV; VELCADE® (bortezomib), a treatment for multiple myeloma; and international sales of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication.

Sales results of TOPAMAX® (topiramate), an antiepileptic and a treatment for migraine, and RISPERDAL® (risperidone), an antipsychotic medication, were negatively impacted by continued generic competition.

During the quarter, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for abiraterone acetate administered with prednisone, an investigational drug for the treatment of metastatic, advanced prostate cancer in patients who have received prior chemotherapy containing a taxane. In addition, the Company submitted supplemental Biologics License Applications to the FDA seeking to expand the SIMPONI® label for the inhibition of structural damage in the treatment of psoriatic arthritis and for REMICADE® (infliximab) for the treatment of moderately to severely active ulcerative colitis in pediatric patients who have had an inadequate response to conventional therapy.

Also during the quarter, Janssen-Cilag International NV filed marketing authorization applications with the European Medicines Agency (EMA) for abiraterone acetate and for telaprevir, an investigational, oral, direct-acting antiviral for the treatment of chronic genotype 1 hepatitis C virus. The Company also received a positive opinion from the EMA's Committee for Medicinal Products for Human Use recommending the granting of a marketing authorization for paliperidone palmitate for the treatment of schizophrenia.

In January 2011, the Company submitted a NDA to the FDA for rivaroxaban, an investigational, oral, once-daily anticoagulant for the prevention of stroke and non-CNS systemic embolism in patients with atrial fibrillation. In addition, the Company announced that the European Commission approved INVEGA® (paliperidone ER), the first antipsychotic schizoaffective treatment in Europe, indicated for treatment of psychotic or manic symptoms.

Worldwide Medical Devices and Diagnostics sales of $24.6 billion for the full-year 2010 represented an increase of 4.4% versus the prior year with an operational increase of 3.4% and a positive impact from currency of 1.0%. Domestic sales increased 3.6%; international sales increased 5.0%, which reflected an operational increase of 3.0% and a positive currency impact of 2.0%.

Primary contributors to operational sales growth included Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive and advanced sterilization products; DePuy's orthopaedic joint reconstruction and sports medicine businesses; Biosense Webster's electrophysiology business; Vistakon's disposable contact lenses; and Ortho-Clinical Diagnostics' products. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued market and competitive pressures in the drug-eluting stent market.

During the quarter, the Company submitted a Biologic License Application to the FDA for the Fibrin Pad, a novel product that combines Ethicon's biomaterials and plasma-derived biologics (Human Fibrinogen and Human Thrombin), to aid in stopping soft tissue bleeding during surgery. In addition, the Company received CE Mark for OneTouch® Verio®Pro, a system for self monitoring of blood glucose levels.

About Johnson & Johnson

Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

* Net earnings and diluted earnings per share excluding special items, such as after-tax restructuring charges, the net impact of litigation settlements, product liability expense and costs associated with the DePuy ASR® Hip recall, are non-GAAP financial measures and should not be considered replacements for GAAP results. A reconciliation of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the Investor Relations section of the Company's website at www.investor.jnj.com.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with members of the investment community to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.

Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm.  These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.investor.jnj.com.

(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Johnson & Johnson and Subsidiaries

Supplementary Sales Data





















(Unaudited; Dollars in Millions)

FOURTH QUARTER


TWELVE MONTHS






Percent Change






Percent Change


2010


2009


Total


Operations


Currency


2010


2009


Total


Operations


Currency

Sales to customers by




















segment of business








































Consumer




















   U.S.

$      1,219


1,712


(28.8)

%

(28.8)


-


$        5,519


6,837


(19.3)

%

(19.3)


-

   International

2,391


2,537


(5.8)


(4.9)


(0.9)


9,071


8,966


1.2


(1.0)


2.2


3,610


4,249


(15.0)


(14.5)


(0.5)


14,590


15,803


(7.7)


(8.9)


1.2





















Pharmaceutical




















   U.S.

3,149


3,338


(5.7)


(5.7)


-


12,519


13,041


(4.0)


(4.0)


-

   International

2,561


2,655


(3.5)


(1.6)


(1.9)


9,877


9,479


4.2


3.4


0.8


5,710


5,993


(4.7)


(3.9)


(0.8)


22,396


22,520


(0.6)


(1.0)


0.4





















Med Devices & Diagnostics




















   U.S.

2,861


2,817


1.6


1.6


-


11,412


11,011


3.6


3.6


-

   International

3,463


3,492


(0.8)


(1.0)


0.2


13,189


12,563


5.0


3.0


2.0


6,324


6,309


0.2


0.1


0.1


24,601


23,574


4.4


3.4


1.0





















U.S.

7,229


7,867


(8.1)


(8.1)


-


29,450


30,889


(4.7)


(4.7)


-

International

8,415


8,684


(3.1)


(2.3)


(0.8)


32,137


31,008


3.6


1.9


1.7

Worldwide

$    15,644


16,551


(5.5)

%

(5.1)


(0.4)


$      61,587


61,897


(0.5)

%

(1.3)


0.8



Johnson & Johnson and Subsidiaries

Supplementary Sales Data





















(Unaudited; Dollars in Millions)

FOURTH QUARTER


TWELVE MONTHS






Percent Change






Percent Change


2010


2009


Total


Operations


Currency


2010


2009


Total


Operations


Currency

Sales to customers by




















geographic area








































U.S.

$      7,229


7,867


(8.1)

%

(8.1)


-


$     29,450


30,889


(4.7)

%

(4.7)


-





















Europe

3,947


4,412


(10.5)


(4.5)


(6.0)


15,510


15,934


(2.7)


0.5


(3.2)

Western Hemisphere excluding U.S.

1,471


1,541


(4.5)


(7.6)


3.1


5,550


5,156


7.6


(0.5)


8.1

Asia-Pacific, Africa

2,997


2,731


9.7


4.2


5.5


11,077


9,918


11.7


5.5


6.2

International

8,415


8,684


(3.1)


(2.3)


(0.8)


32,137


31,008


3.6


1.9


1.7





















Worldwide

$    15,644


16,551


(5.5)

%

(5.1)


(0.4)


$     61,587


61,897


(0.5)

%

(1.3)


0.8



Johnson & Johnson and Subsidiaries 







Condensed Consolidated Statement of Earnings



























(Unaudited; in Millions Except Per Share Figures)

FOURTH QUARTER














2010


2009

Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$         15,644


100.0


$         16,551


100.0


(5.5)

Cost of products sold

5,040


32.2


5,312


32.1


(5.1)

Selling, marketing and administrative expenses

5,180


33.1


5,629


34.0


(8.0)

Research expense

1,982


12.7


2,213


13.4


(10.4)

Interest (income)expense, net

114


0.7


81


0.5



Other (income)expense, net

1,100


7.1


(361)


(2.2)



Restructuring expense

-


-


1,073


6.5



Earnings before provision for taxes on income

2,228


14.2


2,604


15.7


(14.4)

Provision for taxes on income

286


1.8


398


2.4


(28.1)

Net earnings

$           1,942


12.4


$           2,206


13.3


(12.0)





















Net earnings per share  (Diluted)

$             0.70




$             0.79




(11.4)











Average shares outstanding  (Diluted)

2,781.6




2,796.5















Effective tax rate

12.8

%



15.3

%














Adjusted earnings before provision for
 taxes and net earnings









    Earnings before provision for taxes on income

$           3,451

(1)

22.1


$           3,404

(2)

20.6


1.4

    Net earnings

$           2,864

(1)

18.3


$           2,846

(2)

17.2


0.6

    Net earnings per share  (Diluted)

$             1.03

(1)



$             1.02

(2)



1.0

    Effective tax rate

17.0%




16.4%















(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of expense from net litigation settlements of $374 million, $279 million and $0.10 per share, respectively, the exclusion of product liability expense of $569 million, $404 million and $0.14 per share, respectively, and the exclusion of expense for the cost associated with the DePuy ASR® Hip recall program of $280 million, $239 million and $0.09 per share, respectively.  


(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of restructuring expense of $1,186 million ($1,073 million restructuring expense and $113 million related to restructuring included in cost of products sold), $852 million and $0.31 per share, respectively, and the exclusion of income from net litigation settlements of $386 million, $212 million and $0.08 per share, respectively.



Johnson & Johnson and Subsidiaries 







Condensed Consolidated Statement of Earnings



























(Unaudited; in Millions Except Per Share Figures)

TWELVE MONTHS












2010


2009


Percent




Percent




Percent


Increase


Amount


to Sales


Amount


to Sales


(Decrease)

Sales to customers

$         61,587


100.0


$         61,897


100.0


(0.5)

Cost of products sold

18,792


30.5


18,447


29.8


1.9

Selling, marketing and administrative expenses

19,424


31.5


19,801


32.0


(1.9)

Research expense

6,844


11.1


6,986


11.3


(2.0)

Interest (income)expense, net

348


0.6


361


0.6



Other (income)expense, net

(768)


(1.2)


(526)


(0.8)



Restructuring expense

-


-


1,073


1.7



Earnings before provision for taxes on income

16,947


27.5


15,755


25.4


7.6

Provision for taxes on income

3,613


5.8


3,489


5.6


3.6

Net earnings

$         13,334


21.7


$         12,266


19.8


8.7





















Net earnings per share  (Diluted)

$             4.78




$             4.40




8.6











Average shares outstanding  (Diluted)

2,788.8




2,789.1















Effective tax rate

21.3

%



22.1

%














Adjusted earnings before provision for
 taxes and net earnings









    Earnings before provision for taxes on income

$         16,830

(1)

27.3


$         16,555

(2)

26.7


1.7

    Net earnings

$         13,279

(1)

21.6


$         12,906

(2)

20.9


2.9

    Net earnings per share  (Diluted)

$             4.76

(1)



$             4.63

(2)



2.8

    Effective tax rate

21.1%




22.0%















(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of income from net litigation settlements of $966 million, $698 million and $0.25 per share, respectively, the exclusion of product liability expense of $569 million, $404 million and $0.14 per share, respectively, and the exclusion of expense for the cost associated with the DePuy ASR® Hip recall program of $280 million, $239 million and $0.09 per share, respectively.


(2) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings per share (diluted) is the exclusion of restructuring expense of $1,186 million ($1,073 million restructuring expense and $113 million related to restructuring included in cost of products sold), $852 million and $0.31 per share, respectively, and the exclusion of income from fourth quarter net litigation settlements of $386 million, $212 million and $0.08 per share, respectively.



REPORTED SALES vs. PRIOR PERIOD ($MM)



FOURTH QUARTER


TWELVE MONTHS




% Change



% Change


2010

2009

Reported

Operational (1)

Currency


2010

2009

Reported

Operational (1)

Currency

CONSUMER SEGMENT (2)












SKIN CARE












US

352

378

-6.9%

-6.9%

-


1,537

1,582

-2.8%

-2.8%

-

Intl

537

572

-6.1%

-5.5%

-0.6%


1,915

1,885

1.6%

-0.3%

1.9%

WW

889

950

-6.4%

-6.1%

-0.3%


3,452

3,467

-0.4%

-1.4%

1.0%

BABY CARE












US

103

106

-2.8%

-2.8%

-


409

414

-1.2%

-1.2%

-

Intl

474

468

1.3%

1.0%

0.3%


1,800

1,701

5.8%

2.6%

3.2%

WW

577

574

0.5%

0.2%

0.3%


2,209

2,115

4.4%

1.9%

2.5%

ORAL CARE












US

149

167

-10.8%

-10.8%

-


635

716

-11.3%

-11.3%

-

Intl

240

241

-0.4%

-0.9%

0.5%


891

853

4.5%

0.7%

3.8%

WW

389

408

-4.7%

-5.0%

0.3%


1,526

1,569

-2.7%

-4.8%

2.1%

OTC/NUTRITIONALS












US

381

807

-52.8%

-52.8%

-


1,853

2,944

-37.1%

-37.1%

-

Intl

711

767

-7.3%

-5.2%

-2.1%


2,696

2,686

0.4%

-0.8%

1.2%

WW

1,092

1,574

-30.6%

-29.6%

-1.0%


4,549

5,630

-19.2%

-19.8%

0.6%

WOMEN'S HEALTH












US

118

135

-12.6%

-12.6%

-


522

578

-9.7%

-9.7%

-

Intl

332

354

-6.2%

-4.8%

-1.4%


1,322

1,317

0.4%

-1.6%

2.0%

WW

450

489

-8.0%

-7.0%

-1.0%


1,844

1,895

-2.7%

-4.1%

1.4%

WOUND CARE/OTHER












US

116

119

-2.5%

-2.5%

-


563

603

-6.6%

-6.6%

-

Intl

97

135

-28.1%

-27.4%

-0.7%


447

524

-14.7%

-17.8%

3.1%

WW

213

254

-16.1%

-16.1%

0.0%


1,010

1,127

-10.4%

-11.7%

1.3%

TOTAL CONSUMER












US

1,219

1,712

-28.8%

-28.8%

-


5,519

6,837

-19.3%

-19.3%

-

Intl

2,391

2,537

-5.8%

-4.9%

-0.9%


9,071

8,966

1.2%

-1.0%

2.2%

WW

3,610

4,249

-15.0%

-14.5%

-0.5%


14,590

15,803

-7.7%

-8.9%

1.2%













See footnotes on last page












PHARMACEUTICAL SEGMENT  (2) (7)












ACIPHEX/PARIET












US

119

158

-24.7%

-24.7%

-


475

555

-14.4%

-14.4%

-

Intl

133

154

-13.6%

-9.8%

-3.8%


531

541

-1.8%

-1.3%

-0.5%

WW

252

312

-19.2%

-17.3%

-1.9%


1,006

1,096

-8.2%

-7.9%

-0.3%

CONCERTA












US

261

279

-6.5%

-6.5%

-


929

986

-5.8%

-5.8%

-

Intl

107

102

4.9%

5.4%

-0.5%


390

340

14.7%

11.6%

3.1%

WW

368

381

-3.4%

-3.3%

-0.1%


1,319

1,326

-0.5%

-1.3%

0.8%

DURAGESIC/FENTANYL TRANSDERMAL












US

45

53

-15.1%

-15.1%

-


162

216

-25.0%

-25.0%

-

Intl

151

180

-16.1%

-15.6%

-0.5%


586

672

-12.8%

-14.0%

1.2%

WW

196

233

-15.9%

-15.5%

-0.4%


748

888

-15.8%

-16.7%

0.9%

LEVAQUIN/FLOXIN












US

386

433

-10.9%

-10.9%

-


1,312

1,478

-11.2%

-11.2%

-

Intl

14

19

-26.3%

-28.4%

2.1%


45

72

-37.5%

-40.1%

2.6%

WW

400

452

-11.5%

-11.6%

0.1%


1,357

1,550

-12.5%

-12.6%

0.1%

PREZISTA












US

111

88

26.1%

26.1%

-


401

303

32.3%

32.3%

-

Intl

125

91

37.4%

43.9%

-6.5%


456

289

57.8%

59.5%

-1.7%

WW

236

179

31.8%

35.1%

-3.3%


857

592

44.8%

45.7%

-0.9%

PROCRIT/EPREX












US

270

308

-12.3%

-12.3%

-


1,070

1,258

-14.9%

-14.9%

-

Intl

209

268

-22.0%

-18.4%

-3.6%


864

987

-12.5%

-11.7%

-0.8%

WW

479

576

-16.8%

-15.1%

-1.7%


1,934

2,245

-13.9%

-13.6%

-0.3%

REMICADE












US

679

758

-10.4%

-10.4%

-


3,099

3,088

0.4%

0.4%

-

US Exports (3)

381

375

1.6%

1.6%

-


1,487

1,196

24.3%

24.3%

-

Intl

5

5

0.0%

0.0%

0.0%


24

20

20.0%

19.1%

0.9%

WW

1,065

1,138

-6.4%

-6.4%

0.0%


4,610

4,304

7.1%

7.1%

0.0%

RISPERDAL/RISPERIDONE












US

2

24

-91.7%

-91.7%

-


(12)

247

-104.9%

-104.9%

-

Intl

149

169

-11.8%

-13.0%

1.2%


539

652

-17.3%

-19.4%

2.1%

WW

151

193

-21.8%

-22.8%

1.0%


527

899

-41.4%

-42.9%

1.5%

RISPERDAL CONSTA












US

105

133

-21.1%

-21.1%

-


445

519

-14.3%

-14.3%

-

Intl

283

266

6.4%

10.5%

-4.1%


1,055

906

16.4%

17.4%

-1.0%

WW

388

399

-2.8%

-0.1%

-2.7%


1,500

1,425

5.3%

5.9%

-0.6%

TOPAMAX












US

37

89

-58.4%

-58.4%

-


199

731

-72.8%

-72.8%

-

Intl

84

103

-18.4%

-15.6%

-2.8%


339

420

-19.3%

-19.3%

0.0%

WW

121

192

-37.0%

-35.5%

-1.5%


538

1,151

-53.3%

-53.3%

0.0%

VELCADE












US

-

-

-

-

-


-

-

0.0%

0.0%

-

Intl

287

281

2.1%

4.1%

-2.0%


1,080

933

15.8%

15.5%

0.3%

WW

287

281

2.1%

4.1%

-2.0%


1,080

933

15.8%

15.5%

0.3%

OTHER (4)












US

753

640

17.7%

17.7%

-


2,952

2,464

19.8%

19.8%

-

Intl

1,014

1,017

-0.3%

0.4%

-0.7%


3,968

3,647

8.8%

7.0%

1.8%

WW

1,767

1,657

6.6%

7.0%

-0.4%


6,920

6,111

13.2%

12.1%

1.1%

TOTAL PHARMACEUTICAL












US

3,149

3,338

-5.7%

-5.7%

-


12,519

13,041

-4.0%

-4.0%

-

Intl

2,561

2,655

-3.5%

-1.6%

-1.9%


9,877

9,479

4.2%

3.4%

0.8%

WW

5,710

5,993

-4.7%

-3.9%

-0.8%


22,396

22,520

-0.6%

-1.0%

0.4%

MAJOR NEW PHARM PRODUCTS (5)












INVEGA












US

70

72

-2.8%

-2.8%

-


270

266

1.5%

1.5%

-

Intl

46

34

35.3%

37.9%

-2.6%


154

127

21.3%

21.3%

0.0%

WW

116

106

9.4%

10.2%

-0.8%


424

393

7.9%

7.9%

0.0%













See footnotes on last page












MEDICAL DEVICES AND DIAGNOSTICS   (2)












CORDIS (6)












US

246

240

2.5%

2.5%

-


1,008

971

3.8%

3.8%

-

Intl

383

457

-16.2%

-16.3%

0.1%


1,544

1,708

-9.6%

-11.3%

1.7%

WW

629

697

-9.8%

-9.9%

0.1%


2,552

2,679

-4.7%

-5.8%

1.1%

DEPUY












US

807

828

-2.5%

-2.5%

-


3,145

3,096

1.6%

1.6%

-

Intl

640

645

-0.8%

0.0%

-0.8%


2,440

2,276

7.2%

5.2%

2.0%

WW

1,447

1,473

-1.8%

-1.4%

-0.4%


5,585

5,372

4.0%

3.2%

0.8%

DIABETES CARE












US

318

313

1.6%

1.6%

-


1,259

1,221

3.1%

3.1%

-

Intl

326

342

-4.7%

-5.0%

0.3%


1,211

1,219

-0.7%

0.1%

-0.8%

WW

644

655

-1.7%

-1.8%

0.1%


2,470

2,440

1.2%

1.6%

-0.4%

ETHICON












US

501

458

9.4%

9.4%

-


2,000

1,754

14.0%

14.0%

-

Intl

651

651

0.0%

0.6%

-0.6%


2,503

2,368

5.7%

4.0%

1.7%

WW

1,152

1,109

3.9%

4.3%

-0.4%


4,503

4,122

9.2%

8.2%

1.0%

ETHICON ENDO-SURGERY












US

501

532

-5.8%

-5.8%

-


1,975

1,974

0.1%

0.1%

-

Intl

756

724

4.4%

4.6%

-0.2%


2,783

2,518

10.5%

8.4%

2.1%

WW

1,257

1,256

0.1%

0.2%

-0.1%


4,758

4,492

5.9%

4.7%

1.2%

ORTHO-CLINICAL DIAGNOSTICS












US

276

258

7.0%

7.0%

-


1,091

1,104

-1.2%

-1.2%

-

Intl

260

243

7.0%

6.9%

0.1%


962

859

12.0%

9.9%

2.1%

WW

536

501

7.0%

6.9%

0.1%


2,053

1,963

4.6%

3.7%

0.9%

VISION CARE












US

212

188

12.8%

12.8%

-


934

891

4.8%

4.8%

-

Intl

447

430

4.0%

0.7%

3.3%


1,746

1,615

8.1%

3.8%

4.3%

WW

659

618

6.6%

4.3%

2.3%


2,680

2,506

6.9%

4.1%

2.8%

TOTAL MEDICAL DEVICES AND DIAGNOSTICS












US

2,861

2,817

1.6%

1.6%

-


11,412

11,011

3.6%

3.6%

-

Intl

3,463

3,492

-0.8%

-1.0%

0.2%


13,189

12,563

5.0%

3.0%

2.0%

WW

6,324

6,309

0.2%

0.1%

0.1%


24,601

23,574

4.4%

3.4%

1.0%













(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Reported in U.S. sales

(4) Includes December YTD 2010 sales of $393MM for STELARA and $226MM for SIMPONI.

(5) Included in Other

(6) Includes sales of Drug-Eluting Stents for Q4 2010 of $46, $88 and $134MM Domestic, International and Worldwide respectively
     Includes sales of Drug-Eluting Stents for Q4 2009 of $56, $167 and $223MM Domestic, International and Worldwide respectively
     Includes sales of Drug-Eluting Stents for December YTD 2010 of $212, $415 and $627MM Domestic, International and Worldwide respectively
     Includes sales of Drug-Eluting Stents for December YTD 2009 of $245, $674 and $919MM  Domestic, International and Worldwide respectively

(7) Conforms to current presentation



SOURCE Johnson & Johnson

News Provided by Acquire Media